Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The ImproveCareNow Registry: Prediction of different remission rates in pediatric ulcerative colitis.

Created on 16 Sep 2026

Authors

Jonathan Van Hecke, Gigi Veereman, Koen Huysentruyt, Lucas Wauters, Jeremy Adler, Shehzad Saeed, Elisabeth De Greef, and the ImproveCareNow Pediatric IBD Learning Health System

Published in

JPGN reports. Sep 14, 2026. Epub Sep 14, 2026.

Abstract

Identifying predictors of clinical remission in pediatric ulcerative colitis (UC) will impact the therapeutic approach. We aimed to predict time to first (TFR), corticosteroid-free (TCSFR, ≥3 months corticosteroid withdrawal), and sustained remission (TSR, ≥6 months).
This retrospective study analyzed de-identified prospectively collected data from 2383 patients enrolled in ImproveCareNow (2007-2023). We included UC patients under 18 years at diagnosis. Remission was defined as a Pediatric UC Activity Index (PUCAI; <10 points). The Statistical Package for the Social Sciences version 29 with multiple imputation for missing data was used for statistical analysis. Cox regression identified predictors at diagnosis/enrollment (T0) or first visit (T1) on the outcomes (n = 1785). This study received ethics committee approval (23135-ICN_UC).
Mean TFR was 177.7 days, predicted by disease extent (p > 0.05) at T0 and history of severe UC (hazard ratio [HR] = 1.142, p = 0.05) before inclusion. In patients not reaching remission at T1 (subgroup; n = 964), TFR was predicted by PUCAI (confounder; moderate HR = 0.867 or severe disease HR = 0.697, p < 0.1) at T1 and history of severe UC (HR = 1.292, p = 0.007) before T1 (mean 25 days SEM 0.7). Mean TCSFR was 569.6 days, predicted by PUCAI (only mild HR = 0.728 and moderate HR = 0.559, p < 0.001) and use of corticosteroids (HR = 0.668, p < 0.001) at T1 (mean 32 days SEM 0.9). Mean TSR was 631.0 days, predicted by PUCAI (only mild HR = 0.721 and moderate HR = 0.541, p < 0.001) and the use of oral aminosalicylates (HR = 0.793, p = 0.003) at T1 (mean 30 days SEM 0.7).
Several clinical parameters in early disease course predict remission with increasing PUCAI as useful negative predictor.

PMID:
42745752
Bibliographic data and abstract were imported from PubMed on 16 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement